A Monoclonal Antibody to a Carbohydrate Epitope Expressed on Glycolipid and onα3β1Integrin on Human Esophageal Carcinoma

Jamasbi, Roudabeh J.; Stoner, Gary D.; Foote, Linda J.; Lankford, Trish K.; Davern, Sandra; Kennel, Stephen J.

doi:10.1089/153685903771797066

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ELISA was performed as described previously [58]. Briefly, each cell line was cultured in 96-well plates (5×10 4 cells/well) and incubated for 24 hrs at 37°C.…”

Section: Methodsmentioning

confidence: 99%

Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines

Almanaa

Geusz

Jamasbi

2012

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundMany cancers contain cell subpopulations that display characteristics of stem cells. Because these cancer stem cells (CSCs) appear to provide resistance to chemo-radiation therapy, development of therapeutic agents that target CSCs is essential. Curcumin is a phytochemical agent that is currently used in clinical trials to test its effectiveness against cancer. However, the effect of curcumin on CSCs is not well established. The current study evaluated curcumin-induced cell death in six cancer cell lines derived from human esophageal squamous cell carcinomas. Moreover, these cell lines and the ones established from cells that survived curcumin treatments were characterized.MethodsCell loss was assayed after TE-1, TE-8, KY-5, KY-10, YES-1, and YES-2 cells were exposed to 20–80 μM curcumin for 30 hrs. Cell lines surviving 40 or 60 μM curcumin were established from these six original lines. The stem cell markers aldehyde dehydrogenase-1A1 (ALDH1A1) and CD44 as well as NF-κB were used to compare CSC-like subpopulations within and among the original lines as well as the curcumin-surviving lines. YES-2 was tested for tumorsphere-forming capabilities. Finally, the surviving lines were treated with 40 and 60 μM curcumin to determine whether their sensitivity was different from the original lines.ResultsThe cell loss after curcumin treatment increased in a dose-dependent manner in all cell lines. The percentage of cells remaining after 60 μM curcumin treatment varied from 10.9% to 36.3% across the six lines. The cell lines were heterogeneous with respect to ALDH1A1, NF-κB and CD44 expression. KY-5 and YES-1 were the least sensitive and had the highest number of stem-like cells whereas TE-1 had the lowest. The curcumin-surviving lines showed a significant loss in the high staining ALDH1A1 and CD44 cell populations. Tumorspheres formed from YES-2 but were small and rare in the YES-2 surviving line. The curcumin-surviving lines showed a small but significant decrease in sensitivity to curcumin when compared with the original lines.ConclusionOur results suggest that curcumin not only eliminates cancer cells but also targets CSCs. Therefore, curcumin may be an effective compound for treating esophageal and possibly other cancers in which CSCs can cause tumor recurrence.

show abstract

“…ELISA was performed as described previously [58]. Briefly, each cell line was cultured in 96-well plates (5×10 4 cells/well) and incubated for 24 hrs at 37°C.…”

Section: Methodsmentioning

confidence: 99%

Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines

Almanaa

Geusz

Jamasbi

2012

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…Human ESCC lines (KY-5, KY-10, TE-1, TE-8, YES-1, and YES-2) were provided from various sources 41-44, and they were previously characterized immunologically and morphologically in our laboratory 28, 45 Cells were grown in a medium designated as Complete medium that consisted of Dulbecco's modified Eagle medium (DMEM) containing penicillin (100 units/ml), streptomycin (100 µg/ml), L-glutamine (2 mM) (Life Technologies, Grand Island, NY), and 10% fetal bovine serum (FBS, Summit Biotechnology, Ft. Collins, CO). Cells were grown in 100-mm tissue culture dishes (Falcon, Lincoln Park, NJ) at 37°C in 100% humidity and 5% CO 2 .…”

Section: Methodsmentioning

confidence: 99%

A New Method for Identifying Stem-Like Cells in Esophageal Cancer Cell Lines

Almanaa¹,

Geusz²,

Jamasbi³

2013

J. Cancer

Self Cite

View full text Add to dashboard Cite

Cancer stem cells (CSCs) appear to resist chemo-radiotherapy and initiate tumor recurrence in patients. Isolation and further characterization of this subpopulation is important for targeting CSCs. Flow cytometry using Aldefluor, a fluorescent substrate of aldehyde dehydrogenase, has been used to isolate CSCs from various cancer cell lines. However, new techniques are needed to locate and identify CSCs in culture for live-cell analyses such as fluorescence microscopy without introducing artifacts during cell sorting and to observe CSC and non-CSC interactions. Previously, we characterized a distinct CSC subpopulation within human esophageal cancer cell lines (ESCC). In this study we introduce the attached-cell Aldefluor method (ACAM) to detect CSCs in ESCC cell lines (KY-5, KY-10, TE-1, TE-8, YES-1, YES-2). To validate this technique, we isolated CSCs from the YES-2 parental line using standard Aldefluor flow cytometry to create a cell line enriched in CSCs (YES-2CSC). This line showed significantly greater ACAM staining and higher CD44 levels than YES-2. ACAM also showed significantly higher ALDH activity in YES-2CSC than in YES-2S, a cell line that has a diminished CSC subpopulation after having survived treatment with curcumin. ACAM stained cells within tumorspheres made from the CSC-enriched line but not differentiating cells from the tumorspheres. This study also demonstrates a new method for generating and growing tumorspheres without the growth factor supplements normally used in medium to form tumorspheres. ACAM should be evaluated using other cancer cell lines to further substantiate its effectiveness and to characterize CSCs in culture through various imaging techniques.

show abstract

Ovarian cancer proteomics: Many technologies one goal

Narasimhan

Zhao

Choolani

2008

Proteomics Clinical Apps

View full text Add to dashboard Cite

The last decade has seen major changes in the technologies used to identify markers for diagnosing cancer. This review focuses on recent developments on the evolving field of biomarker discovery, and validation techniques using proteomics platforms for ovarian cancer. It is possible now to diagnose various disease conditions using microliter quantities of body fluids. Currently the major developments were made in three distinct areas: (i) protein profiling, (ii) high-throughput validation techniques, and (iii) solid and liquid phase protein microarray platforms for analyzing candidate markers across subclasses and stages of cancers. The recent addition to the long list of technologies is metabolomics using metabolite profiling and informatics-based filtering of information for biomarker discovery of ovarian cancer. Emerging technologies need to address ways to eliminate the limitations posed by the complex dynamic nature of body fluids as well as ways to enrich low-abundance tumor markers if they were to become a successful biomarker discovery tool. These new technologies hold significant promise in identifying more robust markers for ovarian cancer. Since the prevalence of this disease in the population is low, the test must have a high specificity.

show abstract

A Monoclonal Antibody to a Carbohydrate Epitope Expressed on Glycolipid and onα₃β₁Integrin on Human Esophageal Carcinoma

Cited by 4 publications

References 28 publications

Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines

Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines

A New Method for Identifying Stem-Like Cells in Esophageal Cancer Cell Lines

Ovarian cancer proteomics: Many technologies one goal

Contact Info

Product

Resources

About